Neostigmine Bromide CAS: 114-80-7

CAS NO: 114-80-7
Neostigmine Bromide
Chemical Name: Neostigmine bromide
Molecular Formula: C12H19BrN2O2
Formula Weight: 303.2
CAS No.: 114-80-7
Description Review
Description

Neostigmine Bromide is a medication used to treat myasthenia gravis, a neuromuscular disorder that causes muscle weakness and fatigue. It works by inhibiting the breakdown of acetylcholine, a neurotransmitter that is essential for proper muscle function.

Chemical Name:

The chemical name of Neostigmine Bromide is 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium bromide

Molecular Formula:

The molecular formula of Neostigmine Bromide is C12H20BrN2O2.

Formula Weight:

The formula weight of Neostigmine Bromide is 303.21 g/mol.

CAS No:

The CAS number of Neostigmine Bromide is 114-80-7.

Top Ten Keywords from Google and Synonyms:

  1. Myasthenia gravis treatment
  2. Neostigmine Bromide
  3. Acetylcholinesterase inhibitor
  4. Neuromuscular disorder medication
  5. Cholinergic drug
  6. Muscarinic receptor antagonist
  7. Anticholinesterase medication
  8. Parasympathomimetic agent
  9. Muscle weakness therapy
  10. Cholinesterase blocking drug

Synonyms: Prostigmin, Vagostigmin, Neostigmina Bromuro, Kalymin

Health Benefits of Neostigmine Bromide:

Neostigmine Bromide is primarily used to treat myasthenia gravis, a neuromuscular disorder that causes muscle weakness and fatigue. It helps in improving muscle strength and reducing symptoms such as difficulty swallowing and breathing.

Potential Effects:

Neostigmine Bromide is an acetylcholinesterase inhibitor that works by preventing the breakdown of acetylcholine, a neurotransmitter that is essential for proper muscle function. By doing so, it increases the concentration of acetylcholine in the neuromuscular junction, leading to improved muscle function and reduced symptoms of myasthenia gravis. This medication can also have an effect on the gastrointestinal system, causing increased motility and secretion.

Product Mechanism:

Neostigmine Bromide works by inhibiting the activity of acetylcholinesterase, an enzyme responsible for breaking down acetylcholine in the body. By blocking this pathway, Neostigmine Bromide increases the availability of acetylcholine in the neuromuscular junction, leading to improved muscle function and reduced symptoms of myasthenia gravis. The exact mechanism of action is complex, and the effects of Neostigmine Bromide can vary depending on the dose and route of administration.

Safety:

Neostigmine Bromide is generally considered safe when used as directed. However, like all medications, it may cause side effects in some people. It is not recommended for certain patients, such as those with mechanical obstruction of the gastrointestinal or genitourinary tract, asthma, or bradycardia.

Side Effects:

Common side effects of Neostigmine Bromide include nausea, vomiting, and abdominal cramps. Rare but serious side effects may include arrhythmia, bronchospasm, and seizures. Patients who experience any of these symptoms should seek immediate medical attention.

Dosing Information:

The recommended dose of Neostigmine Bromide depends on the condition being treated and the individual patient's response to the medication. For myasthenia gravis, the usual dose is 0.5-2 mg administered intravenously every 2-4 hours as needed. In some cases, oral tablets or transdermal patches may be prescribed.

Conclusion:

Neostigmine Bromide is a medication used to treat myasthenia gravis, a neuromuscular disorder that causes muscle weakness and fatigue. It works by inhibiting the breakdown of acetylcholine, a neurotransmitter that is essential for proper muscle function. While it is generally safe and effective, it may cause side effects in some patients and is not recommended for certain populations. If you have any questions about Neostigmine Bromide or its use, please consult your healthcare provider

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code